US Bancorp’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $107K | Sell |
1,876
-1,797
| -49% | -$98.4K | ﹤0.01% | 2411 |
|
|
2026
Q1 | $207K | Sell |
3,673
-114
| -3% | -$6.65K | ﹤0.01% | 1998 |
|
|
2025
Q4 | $225K | Sell |
3,787
-1,738
| -31% | -$94.6K | ﹤0.01% | 1969 |
|
|
2025
Q3 | $299K | Sell |
5,525
-529
| -9% | -$30.3K | ﹤0.01% | 1800 |
|
|
2025
Q2 | $333K | Sell |
6,054
-446
| -7% | -$26.3K | ﹤0.01% | 1731 |
|
|
2025
Q1 | $459K | Buy |
6,500
+275
| +4% | +$18.5K | ﹤0.01% | 1524 |
|
|
2024
Q4 | $409K | Sell |
6,225
-1,165
| -16% | -$78K | ﹤0.01% | 1606 |
|
|
2024
Q3 | $519K | Sell |
7,390
-4,342
| -37% | -$363K | ﹤0.01% | 1502 |
|
|
2024
Q2 | $966K | Buy |
11,732
+21
| +0.2% | +$1.75K | ﹤0.01% | 1130 |
|
|
2024
Q1 | $1.02M | Sell |
11,711
-2,519
| -18% | -$226K | ﹤0.01% | 1112 |
|
|
2023
Q4 | $1.37M | Sell |
14,230
-51,646
| -78% | -$4.57M | ﹤0.01% | 978 |
|
|
2023
Q3 | $4.06M | Buy |
65,876
+47,007
| +249% | +$4.18M | 0.01% | 590 |
|
|
2023
Q2 | $1.64M | Sell |
18,869
-7,787
| -29% | -$733K | ﹤0.01% | 872 |
|
|
2023
Q1 | $2.59M | Sell |
26,656
-25
| -0.1% | -$2.59K | ﹤0.01% | 719 |
|
|
2022
Q4 | $2.76M | Buy |
26,681
+3,630
| +16% | +$341K | ﹤0.01% | 704 |
|
|
2022
Q3 | $1.95M | Sell |
23,051
-577
| -2% | -$51.4K | ﹤0.01% | 794 |
|
|
2022
Q2 | $1.96M | Sell |
23,628
-5,904
| -20% | -$470K | ﹤0.01% | 820 |
|
|
2022
Q1 | $2.28M | Buy |
29,532
+1,900
| +7% | +$159K | ﹤0.01% | 840 |
|
|
2021
Q4 | $2.44M | Buy |
27,632
+2,557
| +10% | +$211K | ﹤0.01% | 835 |
|
|
2021
Q3 | $1.94M | Sell |
25,075
-68
| -0.3% | -$5.37K | ﹤0.01% | 883 |
|
|
2021
Q2 | $2.1M | Sell |
25,143
-2,908
| -10% | -$231K | ﹤0.01% | 870 |
|
|
2021
Q1 | $2.12M | Sell |
28,051
-26,517
| -49% | -$2.17M | ﹤0.01% | 832 |
|
|
2020
Q4 | $4.79M | Buy |
54,568
+10,462
| +24% | +$829K | 0.01% | 548 |
|
|
2020
Q3 | $3.36M | Sell |
44,106
-999
| -2% | -$101K | 0.01% | 585 |
|
|
2020
Q2 | $5.56M | Buy |
45,105
+2,150
| +5% | +$214K | 0.01% | 460 |
|
|
2020
Q1 | $3.63M | Buy |
42,955
+740
| +2% | +$63.8K | 0.01% | 511 |
|
|
2019
Q4 | $3.57M | Buy |
42,215
+28,487
| +208% | +$2.15M | 0.01% | 603 |
|
|
2019
Q3 | $925K | Buy |
13,728
+4,571
| +50% | +$352K | ﹤0.01% | 1063 |
|
|
2019
Q2 | $785K | Sell |
9,157
-1,040
| -10% | -$89K | ﹤0.01% | 1174 |
|
|
2019
Q1 | $905K | Buy |
10,197
+96
| +1% | +$8.9K | ﹤0.01% | 1108 |
|
|
2018
Q4 | $860K | Sell |
10,101
-131
| -1% | -$12.5K | ﹤0.01% | 1088 |
|
|
2018
Q3 | $993K | Sell |
10,232
-619
| -6% | -$61.8K | ﹤0.01% | 1102 |
|
|
2018
Q2 | $1.02M | Buy |
10,851
+576
| +6% | +$50.4K | ﹤0.01% | 1092 |
|
|
2018
Q1 | $833K | Buy |
10,275
+21
| +0.2% | +$1.8K | ﹤0.01% | 1178 |
|
|
2017
Q4 | $915K | Buy |
10,254
+248
| +2% | +$21.6K | ﹤0.01% | 1134 |
|
|
2017
Q3 | $931K | Buy |
10,006
+1,972
| +25% | +$174K | ﹤0.01% | 1125 |
|
|
2017
Q2 | $730K | Buy |
8,034
+198
| +3% | +$18K | ﹤0.01% | 1220 |
|
|
2017
Q1 | $688K | Sell |
7,836
-109
| -1% | -$9.7K | ﹤0.01% | 1250 |
|
|
2016
Q4 | $658K | Buy |
7,945
+1,345
| +20% | +$116K | ﹤0.01% | 1251 |
|
|
2016
Q3 | $611K | Buy |
6,600
+395
| +6% | +$37.2K | ﹤0.01% | 1262 |
|
|
2016
Q2 | $482K | Sell |
6,205
-492
| -7% | -$41.8K | ﹤0.01% | 1328 |
|
|
2016
Q1 | $553K | Buy |
6,697
+1,022
| +18% | +$83.2K | ﹤0.01% | 1250 |
|
|
2015
Q4 | $595K | Buy |
5,675
+426
| +8% | +$44.5K | ﹤0.01% | 1227 |
|
|
2015
Q3 | $553K | Buy |
5,249
+634
| +14% | +$84.7K | ﹤0.01% | 1252 |
|
|
2015
Q2 | $632K | Buy |
4,615
+1,296
| +39% | +$161K | ﹤0.01% | 1235 |
|
|
2015
Q1 | $414K | Buy |
3,319
+772
| +30% | +$81.8K | ﹤0.01% | 1442 |
|
|
2014
Q4 | $230K | Buy |
2,547
+600
| +31% | +$49.9K | ﹤0.01% | 1708 |
|
|
2014
Q3 | $141K | Sell |
1,947
-644
| -25% | -$42.3K | ﹤0.01% | 1929 |
|
|
2014
Q2 | $162K | Buy |
2,591
+340
| +15% | +$20.5K | ﹤0.01% | 1894 |
|
|
2014
Q1 | $153K | Buy |
2,251
+207
| +10% | +$15.3K | ﹤0.01% | 1905 |
|
|
2013
Q4 | $143K | Sell |
2,044
-2,067
| -50% | -$140K | ﹤0.01% | 1910 |
|
|
2013
Q3 | $297K | Buy |
4,111
+2,687
| +189% | +$179K | ﹤0.01% | 1499 |
|
|
2013
Q2 | $79K | Buy |
+1,424
| New | +$88.7K | ﹤0.01% | 2109 |
|
Other funds holding BMRN
VPC
US Bancorp's BMRN Position: Q2 2026 in Review
US Bancorp reduced its BioMarin Pharmaceuticals (BMRN) stake by 49% in Q2 2026, selling an estimated $98.4K and leaving 1,876 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2411.
US Bancorp first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.56M in Q2 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- US Bancorp held 1,876 shares of BioMarin Pharmaceuticals worth $107K as of Q2 2026.
- US Bancorp sold 1,797 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $98.4K.
- BioMarin Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2411 holding.
- US Bancorp first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- US Bancorp's BioMarin Pharmaceuticals position peaked at $5.56M in Q2 2020.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.